A medical doctor accredited by the ECFMG. He worked in Lexingen Pharmaceuticals and Synta Pharmaceuticals respectively during his stay in the United States. He has served as a pharmacological researcher, department manager and deputy director of R&D at various stages of technical and managerial positions. Involved in four projects of new drug research and development and IND declaration, one into the United States clinical phase III, two into phase II. In 2003, he joined Hutchison Whampoa Pharmaceutical (Shanghai) Co., Ltd. as Senior Research and Development Director of the Department of Pharmacology. He was responsible for pharmacological research and IND declaration of five projects. He organized and participated in the first new drug research and development and IND declaration in China to complete the phase II study. Since 2008, as one of the founders of Pengli Biomedical Technology (Shanghai) Co., Ltd, he built the largest international standard pre-clinical pharmacodynamics comprehensive evaluation platform in China. In 2011, he won the honor of entrepreneurship experts in Shanghai.
He is currently the chief technology consultant of Xuhui Analysis Co., Ltd.